← Search & browse all drugs
VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for gastric secretion
pentagastrin
V04CG04
Forms & Strengths
- Sterile aqueous solution for injection, 0.1 mg/mL (100 µg/mL) vials
- Powder for reconstitution to 100 µg/mL
Adult Dosing
- Gastric acid test: 0.5 µg/kg IV bolus over 1 min, repeat q15 min up to 5 doses (max 5 µg/kg)
- Calcitonin stimulation (medullary thyroid carcinoma): 0.5 µg/kg IV bolus
- CCK gallbladder ejection test: 6 µg/kg IV over 2 min
- Historical ulcer therapy: 0.5 µg/kg SC daily for 10‑14 days
Pediatric Dosing
- Diagnostic use (acid or calcitonin test): 0.5 µg/kg IV bolus, max total 5 µg/kg
- CCK test: 6 µg/kg IV (limited data, use adult protocol)
- Not recommended for children <1 yr or with severe cardiac disease
Indications
- Provocative gastric acid secretion test for Zollinger‑Ellison syndrome
- Calcitonin stimulation test for medullary thyroid carcinoma surveillance
- Cholecystokinin test to assess gallbladder ejection fraction
- Adjunctive therapy for chronic gastric ulcer (rare, off‑label)
Mechanism of Action
- Synthetic gastrin analog binds CCK‑B/gastrin receptors on ECL and parietal cells
- Stimulates histamine release → increased H⁺ secretion
- Induces calcitonin release from thyroid C‑cells
- Enhances gallbladder contraction via CCK‑like activity
Contraindications
- Known hypersensitivity to pentagastrin or any peptide component
- Pheochromocytoma or uncontrolled hypertension
- Recent myocardial infarction or unstable coronary artery disease
- Active perforated peptic ulcer or severe gastrointestinal hemorrhage
Adverse Reactions
- Flushing, warmth, or erythema
- Nausea, vomiting, abdominal cramps
- Transient hypotension or hypertension, tachycardia
- Bronchospasm in asthmatic patients
- Headache, dizziness, hyperglycemia
Drug Interactions
- Adrenergic agonists may exacerbate hypertensive response
- Beta‑blockers can precipitate severe hypertension with pentagastrin
- Anticholinergics or H2‑blockers/PPIs blunt gastric acid response
- Cholinesterase inhibitors may augment secretory effects
- Diuretics may increase risk of electrolyte shifts
Curated Content: Needs Vetting Before Put to Clinical Use